Vernakalant
- Generic Name
- Vernakalant
- Brand Names
- Brinavess
- Drug Type
- Small Molecule
- Chemical Formula
- C20H31NO4
- CAS Number
- 794466-70-9
- Unique Ingredient Identifier
- 9G468C8B13
- Background
Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is...
- Indication
Indicated for the rapid conversion of recent onset of atrial fibrillation to sinus rhythm in adults for non-surgery patients that lasts for less than 7 days of duration and post-cardiac surgery patients with atrial fibrillation lasting less than 3 days of duration.
- Associated Conditions
- Atrial Fibrillation
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.